Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine
2. Tak 438
3. Tak-438
4. Tak438
5. Vonoprazan
1. Tak-438
2. 1260141-27-2
3. 881681-01-2
4. Vonoprazan Fumurate
5. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Fumarate
6. Tak 438
7. Tak-438 Monofumarate
8. Vonoprazan Monofumarate
9. Vonoprazan Fumarate (tak-438)
10. 4qw3x4amlb
11. Tak438
12. Unii-4qw3x4amlb
13. Takecab
14. Vocinti
15. (e)-but-2-enedioic Acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-n-methylmethanamine
16. 1h-pyrrole-3-methanamine, 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-, (2e)-2-butenedioate (1:1)
17. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Xfumarate
18. 1h-pyrrole-3-methanamine, 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-, 2-butenedioate (1:1)
19. Mfcd18633280
20. Vonoprazan Monofumurate
21. 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine Fumarate
22. Takecab (tn)
23. Vonoprazan Fumarate [usan]
24. Schembl194394
25. Schembl194396
26. Chembl2064032
27. Vonoprazan Fumarate [mi]
28. Vonoprazan Fumarate (jan/usan)
29. Ex-a097
30. Vonoprazan Fumarate [jan]
31. Bcp05635
32. Bcp13238
33. Ex-a4001
34. S8016
35. Vonoprazan Fumarate [who-dd]
36. Akos027251052
37. Ccg-269350
38. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Monofumarate
39. 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-1h-pyrrole-3-methanamine (2e)-2-butenedioate
40. Ac-29287
41. Ac-29309
42. Ds-12234
43. Ls-14849
44. Cs-0164592
45. Sw220126-1
46. D10466
47. A854789
48. A900258
49. J-524312
50. Q25104163
51. Tak438 Fumarate;tak-438 Fumarate;tak 438 Fumarate;1260141-27-2
52. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Fumarate? (vonoprazan Impurity Pound(c)
53. 2098974-13-9
54. 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-1h-pyrrole-3-methanamine 2-butenedioate
| Molecular Weight | 461.5 g/mol |
|---|---|
| Molecular Formula | C21H20FN3O6S |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | 461.10568470 g/mol |
| Monoisotopic Mass | 461.10568470 g/mol |
| Topological Polar Surface Area | 147 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 629 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35150
Submission : 2020-08-31
Status : Active
Type : II
NDC Package Code : 42765-014
Start Marketing Date : 2020-08-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (5kg/5kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2025-01-24
Registration Number : Su289-26-ND
Manufacturer Name : Metrochem API Private Limited
Manufacturer Address : Plot No. 34B, 40B & 60B, JN Pharma City, Thanam Village, Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40356
Submission : 2024-12-29
Status : Active
Type : II
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39107
Submission : 2023-11-02
Status : Active
Type : II
Date of Issue : 2024-01-15
Valid Till : 2027-01-14
Written Confirmation Number : SD240003
Address of the Firm :
Registrant Name : Farmia Co., Ltd.
Registration Date : 2025-01-23
Registration Number : Su719-2-ND
Manufacturer Name : Shandong Chenghui Shuangda Pharmaceutical Co.,Ltd.
Manufacturer Address : Economic Development Zone,Pingyuan County, DezhouCity, Shandong, PRChina
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42655
Submission : 2025-09-26
Status : Active
Type : II
| Available Reg Filing : ASMF |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
NDC Package Code : 52696-0010
Start Marketing Date : 2023-11-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39528
Submission : 2024-02-29
Status : Active
Type : II
Date of Issue : 2025-10-01
Valid Till : 2028-09-30
Written Confirmation Number : WC-0191
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36262
Submission : 2021-09-06
Status : Active
Type : II
Date of Issue : 2025-08-05
Valid Till : 2028-06-25
Written Confirmation Number : WC-0054
Address of the Firm :
Registrant Name : Jinyang Pharmaceutical Co., Ltd.
Registration Date : 2025-10-10
Registration Number : Su69-12-ND(1)
Manufacturer Name : Ami Lifesciences Private Limited
Manufacturer Address : Block No. 82/B, ECP Road At & Post. Karakhadi, Tal-Padra, City : Karakhadi-391450, Dist : Vadodara, Gujarat State India
| Available Reg Filing : BR, CN |
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35150
Submission : 2020-08-31
Status : Active
Type : II
Zhejiang Hengkang Pharm Group is a dynamic pharmaceutical entity, spanning drug research, large-scale production, and global marketing.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40356
Submission : 2024-12-29
Status : Active
Type : II
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39107
Submission : 2023-11-02
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42655
Submission : 2025-09-26
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39528
Submission : 2024-02-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36262
Submission : 2021-09-06
Status : Active
Type : II
Honour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40334
Submission : 2025-01-08
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38293
Submission : 2023-04-17
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32831
Submission : 2018-06-26
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37923
Submission : 2023-01-05
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
Date of Issue : 2024-01-15
Valid Till : 2027-01-14
Written Confirmation Number : SD240003
Address of the Firm : Economic Development Zone, Pingyuan County, Dezhou City, Shandong, PR China
Date of Issue : 2025-10-01
Valid Till : 2028-09-30
Written Confirmation Number : WC-0191
Address of the Firm : Sy. No. 10, Gaddapotharam (V), Jinnaram (M), Sangareddy District 502319, Telanga...
Date of Issue : 2025-08-05
Valid Till : 2028-06-25
Written Confirmation Number : WC-0054
Address of the Firm : Block No. 82/B, ECP Road, At & Post Karakhadi, Tal - Padra, Dist. Baroda, Gujara...
Date of Issue : 2025-07-24
Valid Till : 2028-06-16
Written Confirmation Number : WC-0050
Address of the Firm : (Morepen Village), Village Malkumajra, Baddi-Nalagarh Road, Baddi, Distt. Solan,...

Date of Issue : 2022-08-04
Valid Till : 2025-06-16
Written Confirmation Number : WC-050
Address of the Firm : (Unit-IV), (Morepen Village), Village Malkumajra, Baddi-Nalagarh Road, Baddi, Di...

Date of Issue : 2025-08-08
Valid Till : 2028-07-25
Written Confirmation Number : WC-0027
Address of the Firm : Unit-ll, Sy. No. 14, Gaddapotharam Village, IDA, Khazipally, Jinnaram Mandal, Sa...

Date of Issue : 2025-09-12
Valid Till : 2028-07-02
Written Confirmation Number : WC-0182
Address of the Firm : Unit I, Survey No. 239 & 240, Dothigudem (V), Pochampally (M), Yadadri Bhuvanagi...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Voquezna Triple Pack
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Phathom Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 24, 2022
Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Phathom Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Evonik and Phathom Pharmaceuticals Partner to Produce Novel Acid-Blocker Vonoprazan
Details : Vonoprazan is a novel potassium-competitive acid blocker (PCAB). It inhibits gastric acid secretion by acting as a reversible competitive inhibitor against potassium ions.
Product Name : Voquezna Triple Pack
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 24, 2022
Details:
Voquezna Triple Pak (vonoprazan) is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Helicobacter Infections.
Lead Product(s): Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area: Infections and Infectious Diseases Brand Name: Voquezna Triple Pak
Study Phase: Phase IVProduct Type: Miscellaneous
Sponsor: Phathom Pharmaceuticals | NRG Oncology
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 03, 2025

Lead Product(s) : Vonoprazan Fumarate,Amoxicillin Trihydrate,Clarithromycin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Phathom Pharmaceuticals | NRG Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
Details : Voquezna Triple Pak (vonoprazan) is a small molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Helicobacter Infections.
Product Name : Voquezna Triple Pak
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Voquezna (vonoprazan) is a potassium-competitive acid blocker, indicated for heartburn associated with Non-Erosive GERD.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Voquezna
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 06, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phathom Gets FDA Nod for 10 Years of Regulatory Exclusivity for Voquezna
Details : Voquezna (vonoprazan) is a potassium-competitive acid blocker, indicated for heartburn associated with Non-Erosive GERD.
Product Name : Voquezna
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 06, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Eosinophilic Esophagitis.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 28, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Eosinophilic Esophagitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 28, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 18, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Stomach Ulcer.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vonoprazan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Stomach Ulcer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 15, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Lupivon (vonoprazan), a novel potassium-competitive acid blocker, in India.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Lupivon
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lupin Partners with Takeda to Commercialise Vonoprazan
Details : Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Lupivon (vonoprazan), a novel potassium-competitive acid blocker, in India.
Product Name : Lupivon
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The licensing deal will enhance Alkem's offerings in the gastrointestinal segment by including Vonzai (vonoprazan), a first-in-class potassium-competitive acid blocker.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Vonzai
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Alkem Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Alkem Laboratories
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Alkem Inks Licensing Pact with Takeda to Introduce Vonoprazan in India
Details : The licensing deal will enhance Alkem's offerings in the gastrointestinal segment by including Vonzai (vonoprazan), a first-in-class potassium-competitive acid blocker.
Product Name : Vonzai
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 03, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Phathom intends to use the net proceeds from the offering to fund commercialization expenses and further clinical development of Voquezna (vonoprazan) for the treatment of Erosive GERD.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Voquezna
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Evercore ISI
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering August 19, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Evercore ISI
Deal Size : $130.0 million
Deal Type : Public Offering
Phathom Pharmaceuticals Prices $130M Offering of Common Stock, Pre-Funded Warrants
Details : Phathom intends to use the net proceeds from the offering to fund commercialization expenses and further clinical development of Voquezna (vonoprazan) for the treatment of Erosive GERD.
Product Name : Voquezna
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 19, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Under the terms of this agreement, Takeda has granted Zydus non-exclusive patent licensing rights for the commercialization of Vault (vonoprazan) in India.
Lead Product(s): Vonoprazan Fumarate,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Vault
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Zydus Lifesciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 19, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Vonoprazan Fumarate,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Zydus Lifesciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Zydus signs patent licensing agreement with Takeda for 'VaultA’ in India
Details : Under the terms of this agreement, Takeda has granted Zydus non-exclusive patent licensing rights for the commercialization of Vault (vonoprazan) in India.
Product Name : Vault
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 19, 2024

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]5-(2-fluorophenyl)-1H-pyrrole-3- carbonitrile
CAS Number : 1240948-77-9
End Use API : Vonoprazan Fumarate
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in R&D and production of APIs and advanced intermediates, CDMO/CRO/OEM, and Technology Transfer ...
5-(2-fluorophenyl)-1H-Pyrrole-3- carboxaldehyde
CAS Number : 881674-56-2
End Use API : Vonoprazan Fumarate
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in R&D and production of APIs and advanced intermediates, CDMO/CRO/OEM, and Technology Transfer ...
Pyridine-3-sulfonyl chloride hydrochloride
CAS Number : 16133-25-8
End Use API : Vonoprazan Fumarate
About The Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in R&D and production of APIs and advanced intermediates, CDMO/CRO/OEM, and Technology Transfer ...
Pyridine-3-Sulfonyl Chloride Hydrochloride
CAS Number : 16133-25-8
End Use API : Vonoprazan Fumarate
About The Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our cor...
5-(2-Fluorophenyl)-1H-pyrrole-3-carbaldehyde
CAS Number : 881674-56-2
End Use API : Vonoprazan Fumarate
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe ...
CAS Number : 16133-25-8
End Use API : Vonoprazan Fumarate
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe ...
5-(2-Fluorophenyl)-1-(pyridine-3-sulfonyl)-1H- pyr...
CAS Number : 807-719-6
End Use API : Vonoprazan Fumarate
About The Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe ...
CAS Number : 16133-25-8
End Use API : Vonoprazan Fumarate
About The Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...
5-(2-fluorophenyl)-1H- Pyrrole-3-carboxaldehyde
CAS Number : 881674-56-2
End Use API : Vonoprazan Fumarate
About The Company : Headquartered in Fengxian District, Shanghai Minbiotech Co., Ltd. is a company specializing in the R&D and production of advanced pharmaceutical intermediate...
5-(2-Fluorophenyl)-1H-pyrrole-3-carboxaldehyde
CAS Number : 881674-56-2
End Use API : Vonoprazan Fumarate
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
36
PharmaCompass offers a list of Vonoprazan Fumarate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vonoprazan Fumarate manufacturer or Vonoprazan Fumarate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vonoprazan Fumarate manufacturer or Vonoprazan Fumarate supplier.
PharmaCompass also assists you with knowing the Vonoprazan Fumarate API Price utilized in the formulation of products. Vonoprazan Fumarate API Price is not always fixed or binding as the Vonoprazan Fumarate Price is obtained through a variety of data sources. The Vonoprazan Fumarate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Vonoprazan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vonoprazan, including repackagers and relabelers. The FDA regulates Vonoprazan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vonoprazan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Vonoprazan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Vonoprazan supplier is an individual or a company that provides Vonoprazan active pharmaceutical ingredient (API) or Vonoprazan finished formulations upon request. The Vonoprazan suppliers may include Vonoprazan API manufacturers, exporters, distributors and traders.
click here to find a list of Vonoprazan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Vonoprazan DMF (Drug Master File) is a document detailing the whole manufacturing process of Vonoprazan active pharmaceutical ingredient (API) in detail. Different forms of Vonoprazan DMFs exist exist since differing nations have different regulations, such as Vonoprazan USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Vonoprazan DMF submitted to regulatory agencies in the US is known as a USDMF. Vonoprazan USDMF includes data on Vonoprazan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Vonoprazan USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Vonoprazan suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Vonoprazan Drug Master File in Korea (Vonoprazan KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Vonoprazan. The MFDS reviews the Vonoprazan KDMF as part of the drug registration process and uses the information provided in the Vonoprazan KDMF to evaluate the safety and efficacy of the drug.
After submitting a Vonoprazan KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Vonoprazan API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Vonoprazan suppliers with KDMF on PharmaCompass.
A Vonoprazan written confirmation (Vonoprazan WC) is an official document issued by a regulatory agency to a Vonoprazan manufacturer, verifying that the manufacturing facility of a Vonoprazan active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Vonoprazan APIs or Vonoprazan finished pharmaceutical products to another nation, regulatory agencies frequently require a Vonoprazan WC (written confirmation) as part of the regulatory process.
click here to find a list of Vonoprazan suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Vonoprazan as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Vonoprazan API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Vonoprazan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Vonoprazan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Vonoprazan NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Vonoprazan suppliers with NDC on PharmaCompass.
Vonoprazan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vonoprazan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vonoprazan GMP manufacturer or Vonoprazan GMP API supplier for your needs.
A Vonoprazan CoA (Certificate of Analysis) is a formal document that attests to Vonoprazan's compliance with Vonoprazan specifications and serves as a tool for batch-level quality control.
Vonoprazan CoA mostly includes findings from lab analyses of a specific batch. For each Vonoprazan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vonoprazan may be tested according to a variety of international standards, such as European Pharmacopoeia (Vonoprazan EP), Vonoprazan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vonoprazan USP).